# Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

> **NCT04927585** · PHASE1 · COMPLETED · sponsor: **Worcester HIV Vaccine** · enrollment: 42 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** env (A,B,C,A/E)/gag (C) DNA Vaccine
- **BIOLOGICAL:** gp120 (A,B,C,A/E) Protein Vaccine
- **BIOLOGICAL:** GLA-SE adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04927585
- **Lead sponsor:** Worcester HIV Vaccine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2023-12-07
- **Final completion:** 2023-12-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04927585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04927585, "Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04927585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*